An Open- Label, Phase 2, Multicenter Feasibility Study if Manualized MDMA-Assisted Psychotherapy with an Optional fMRI sub-study Assessing Changes in Brain Activity in Subjects with Posttraumatic Stress Disorder
Latest Information Update: 30 Jan 2025
At a glance
- Drugs Methylenedioxymetamfetamine (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- Sponsors MAPS Europe B.V.
Most Recent Events
- 24 Apr 2024 According to a Lykos Therapeutics media release, company announced completion of this study.
- 08 Feb 2024 This trial has been discontinued in Spain.
- 06 Feb 2024 Status changed from recruiting to completed.